In our current study, we found that the expression trends of SFRP2 were consistent with those of SFRP1 in acute AD patients, and the patients with high levels of SFRP2 showed fewer end-point events and a better prognosis. The gene discussed is SFRP2; the disease is Alzheimer disease.